Considering the impact of different mutation types on the GBA1 phenotype, it is necessary to stratify patients according to the GBA1 mutation type, include more homozygous and complex congenic carriers (GD-PD), and exclude common PD-associated genes such as LRRK2 and PRKN from clinical trials [71, 73, 82, 102, 103]. The gene discussed is LRRK2; the disease is Parkinson disease.